D
David A. Cooper
Researcher at Pfizer
Publications - 965
Citations - 81765
David A. Cooper is an academic researcher from Pfizer. The author has contributed to research in topics: Acquired immunodeficiency syndrome (AIDS) & Viral load. The author has an hindex of 117, co-authored 903 publications receiving 69249 citations. Previous affiliations of David A. Cooper include Boston Children's Hospital & National Institutes of Health.
Papers
More filters
Journal ArticleDOI
Raltegravir and unboosted atazanavir dual therapy in virologically suppressed antiretroviral treatment-experienced HIV patients
TL;DR: Dual therapy with ATV plus RAL maintained viral suppression in this small group of highly ART-experienced patients, implying no disadvantage from switching to dual therapy.
Journal ArticleDOI
Creation of a drug fund for post-clinical trial access to antiretrovirals.
Jintanat Ananworanich,Theshinee Cheunyam,Somsong Teeratakulpisarn,Mark A. Boyd,Kiat Ruxrungtham,Joep M. A. Lange,David A. Cooper,Praphan Phanuphak +7 more
TL;DR: The proposed revision to paragraph 30 of the Declaration of Helsinki would introduce two main changes: that the physician should make every effort to see that patients receive treatment once it has been approved by appropriate authorities and that the doctor is required to explicitly tell patients if they are unlikely to continue receiving treatment from sponsors after they leave the study.
Journal Article
Gay youth and their precautionary sexual behaviors: the Sydney men and sexual health study.
P. Van De Ven,Jason Noble,Susan Kippax,Garrett Prestage,June Crawford,Don Baxter,David A. Cooper +6 more
TL;DR: Although young men in this cohort were more likely to be of unknown serostatus, they were at least as knowledgeable, as attached to gay community, and as precautionary in their sexual behaviors with regular and casual male partners as their older counterparts.
Journal ArticleDOI
Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
Jason C. Kovacic,Allison Martin,Dianne Carey,Handan Wand,Patrick W. G. Mallon,Michael P. Feneley,Sean Emery,David A. Cooper,Andrew Carr +8 more
TL;DR: Rosiglitazone has minimal effect on flow-mediated dilation in HIV-infected lipoatrophic adults and despite worsening of the lipid profile, the overall effect of rosig litazone on the cardiovascular risk profile in these subjects was positive.
Journal ArticleDOI
Kaposi sarcoma risk in HIV-infected children and adolescents on combination antiretroviral therapy from sub-Saharan Africa, Europe, and Asia
Cohere in EuroCoord,Eliane Rohner,Kurt Schmidlin,Marcel Zwahlen,Rana Chakraborty,Gary M. Clifford,Niels Obel,Sophie Grabar,Annelies Verbon,Antoni Noguera-Julian,Ali Judd,Intira Jeannie Collins,Pablo Rojo,Norbert H. Brockmeyer,Maria Campbell,Geneviève Chêne,Hans Prozesky,Brian Eley,D. Cristina Stefan,Alan Davidson,Cleophas Chimbetete,Shobna Sawry,Mary-Ann Davies,Azar Kariminia,Ung Vibol,Annette H. Sohn,Matthias Egger,Julia Bohlius,Frank Tanser,Michael J. Vinikoor,Eusebio Macete,Robin Wood,Kathryn Stinson,Daniela Garone,Geoffrey Fatti,Sam Phiri,Janet Giddy,Kennedy Malisita,Christiane Fritz,Michael Hobbins,Kamelia Kamenova,Matthew P. Fox,Karl Technau,Robert Zangerle,Giota Touloumi,Josiane Warszawski,Laurence Meyer,François Dabis,Murielle Mary Krause,Jade Ghosn,Catherine Leport,Linda Wittkop,Peter Reiss,Ferdinand W. N. M. Wit,Maria Prins,Heiner C. Bucher,Caroline A. Sabin,Diana M. Gibb,Gerd Fätkenheuer,Julia del Amo,Claire Thorne,Amanda Mocroft,Ole Kirk,Christoph Stephan,Santiago Pérez-Hoyos,Osamah Hamouda,Barbara Bartmeyer,Nikoloz Chkhartishvili,Andrea Antinori,Antonella d'Arminio Monforte,Luis Prieto,Antoni Soriano-Arandes,Manuel Battegay,Roger D. Kouyos,Cristina Mussini,Pat A Tookey,Jordi Casabona,José M. Miró,Antonella Castagna,Deborah Konopnick,Tessa Goetghebuer,Anders Sönnerborg,Carlo Torti,Ramón Teira,Myriam Garrido,David Haerry,Stéphane De Wit,Dominique Costagliola,Dorthe Raben,Diana Barger,Christine Schwimmer,Monique Termote,Casper M Frederiksen,Nina Friis-Møller,Juan Berenguer,Vincent Bouteloup,Alessandro Cozzi-Lepri,Mary-Anne Davies,Maria Dorrucci,David Dunn,Hansjakob Furrer,Marguerite Guiguet,Olivier Lambotte,Valériane Leroy,Sara Lodi,Sophie Matheron,Susana Monge,Fumiyo Nakagawa,Roger Paredes,Lars Peters,Andrew N. Phillips,Massimo Puoti,Michael Schomaker,Colette Smit,Jonathan A C Sterne,Rodolphe Thiébaut,Marc van der Valk,P. S. Ly,Vohith Khol,S. M. Sarun,V. B. Ung,Joseph D. Tucker,N. Kumarasamy,Suneeta Saghayam,Ezhilarasi Chandrasekaran,Dewi Kumara Wati,L. P. P. Atmikasari,I. Y. Malino,Nia Kurniati,Dina Muktiarti,S. M. Fong,M. Lim,F. Daut,Nik Khairulddin Nik Yusoff,P. Mohamad,Karina Razali,Thahira Jamal Mohamed,N. A. D. R. Mohammed,Revathy Nallusamy,K. C. Chan,Tavitiya Sudjaritruk,Virat Sirisanthana,Linda Aurpibul,Peninnah Oberdorfer,Rawiwan Hansudewechakul,S. Denjanta,W. Srisuk,A. Kongphonoi,Pagakrong Lumbiganon,Pope Kosalaraksa,P. Tharnprisan,T. Udomphanit,Gonzague Jourdain,Torsak Bunupuradah,Thanyawee Puthanakit,Wasana Prasitsuebsai,W. Chanthaweethip,Kulkanya Chokephaibulkit,Keswadee Lapphra,Wanatpreeya Phongsamart,Sirintip Sricharoenchai,K. H. Truong,Q. T. Du,C. H. Nguyen,V. C. Do,T. M. Ha,V. T. An,L. V. Nguyen,D. T. K. Khu,A. N. Pham,L. T. Nguyen,O. N. Le,A. H. Sohn,Chuenkamol Sethaputra,David A. Cooper,Matthew Law,A. Kariminia +176 more
TL;DR: HIV-infected children from SSA but not those from other regions, have a high risk of developing Kaposi sarcoma after cART initiation, and early cart initiation in these children might reduce KS risk.